531. Prioritize an optimized strategy of effective, evidence-based case-finding testing approaches to increase demand for testing of children of all ages and improve patient identification, including HIV testing all children attending malnutrition, TB, and inpatient wards, tracking of mother-infant pairs and opportune testing points, scaling up index testing, etc.

​

532. Support MTCT, viral suppression and retention in treatment and care (of pregnant and breastfeeding women as well as HIV-positive infants and children) through consistent provision of viral load testing and consideration for point-of-care viral load for prioritized populations (ie. infants and children, pregnant and breastfeeding women, etc).

​

533. Develop more accurate, transparent, and consolidated forecasts (through data collection and public reporting on diagnostics uptake and implementation) to support manufacturing, improve supply chain management, and reagent availability as well as to support national, regional or global pooled procurement and related activities and to track progress.

​

534. Prioritize implementation and documentation of the final diagnosis / outcome after the period of risk for transmission of HIV-exposed infants (at 18 months of age or 3 months post-cessation of breastfeeding, whichever is later).

​

535. Implement legal provisions and national programs for post market surveillance of diagnostic products that include procedures and tools for supplier responsibilities and reporting incidents and field safety corrective actions promptly to the national regulator.

 

536. Increase availability and coverage of point-of-care infant diagnosis and viral load through expansion of devices from 130 to 340 by December 2023.

​

537. Strengthen sample transportation through modalities whereby Tanzania Postal Transportation will urgently engage PPP modalities and hire private vendors to fast-track sample transportation and reduce the turnaround times.

 

538. Complete the diagnostic network optimization assessment, including cost analyses, for HIV infant diagnosis, HIV viral load, and tuberculosis.

​

539. Expand identification of HIV-exposed infants through integration with child immunization and nutrition programs through implementation of a countrywide standard operating procedure for rapid registration.

​

Treatment

​

540. Accelerate transition to more optimal regimens and formulations as described in WHO Guidelines and 2018 Optimal formulary by:

i. Developing transition plans by Q1 2019
ii. Introducing DTG 50 mg for children above 25 kg by Q2 2019

iii. Fully phasing out NVP based regimens by Q3 2019 in children older than 3 years and by Q2 2020 in children younger than 3 years.

iv. Optimizing the use of LPVr solid formulations by prioritizing infants and children that most need them as well as using LPVr tablets as soon as a child can swallow them

v. Transitioning stable children to optimal regimens as outlined by in the WHO treatment guidelines and in the Optimal Formulary and Limited Use List

 

541. Increase viral load monitoring of children and ensure linkage of children failing first line drugs to 2nd and 3rd line drugs, working with donors and manufacturers to ensure availability of drugs in line with WHO guidelines.

​

542. Support MTCT, viral suppression and retention in treatment and care (of pregnant and breastfeeding women as well as HIV-positive infants and children) through consistent provision of viral load testing and consideration for point-of-care viral load for prioritized populations (ie. infants and children, pregnant and breastfeeding women, etc).